An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars. READ MORE

Research in Review

A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.

READ MORE

Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.

READ MORE

Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.

READ MORE

A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.

READ MORE